Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.24.2.u1
Revenues from Contracts and Significant Customers (Tables)
6 Months Ended
Jun. 30, 2024
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Three months ended June 30, 

Six Months Ended June 30, 

    

2024

    

2023

    

2024

    

2023

Revenue

Qbrexza

$

6,836

$

8,079

$

11,853

$

12,173

Accutane

5,719

5,579

11,538

10,227

Amzeeq

1,205

1,374

1,960

2,568

Zilxi

369

572

642

886

Other / legacy product revenue

726

1,357

1,892

3,272

Collaboration revenue

183

364

Revenue – related party

 

41

 

31

 

41

 

66

Other revenue

211

 

259

Total net revenue

$

14,896

$

17,386

$

27,926

$

29,815